Zymeworks (ZYME) announced the U.S. FDA has cleared the investigational new drug application for ZW251, a novel glypican-3-targeted ADC incorporating the company’s proprietary topoisomerase 1 inhibitor payload, ZD06519, for the treatment of HCC. The company plans to commence Phase 1 clinical studies for ZW251 in 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks to Announce Q2 2025 Financials and Engage in Investor Conferences
- Positive Buy Rating for Zymeworks Amid Promising Clinical Trials and Strategic Partnerships
- Zymeworks: Hold Rating Amid Uncertain Market Potential and Upcoming Catalysts
- Zymeworks Gains Momentum with European Approval and Promising Financial Milestones for Zanidatamab
- Zymeworks Amends Warrant Agreement with EcoR1 Capital